Abstract
Purpose of reviewEndogenous Cushing's syndrome (CS) is associated with increased patient morbidity (hypertension, diabetes mellitus, dyslipidemia, visceral obesity, osteoporosis, cognitive alterations, and impaired quality of life). Both arterial and venous thromboembolic events (TE) due to alterations in the hemostatic system and prothrombotic state are widely reported in patients with CS, more so postoperatively. Increased mortality, if not appropriately treated, is largely due to cardiovascular events and infections.Recent findingsPatients with CS have markedly increased risk of thromboembolic episodes compared to the general population. The prothrombotic state is mediated by increased levels of procoagulant factors, but also by an impaired fibrinolytic capacity. All contribute to TE, atherosclerosis, and subsequent cardiovascular morbidity and mortality. Some abnormalities progressively improve after CS remission, but do not fully normalize for at least 1 year or more.SummaryDue to the additional thrombotic risk of surgery or any invasive procedure, anticoagulation prophylaxis should be at least considered in patients with CS and balanced with individual bleeding risk. However, a clear protocol of thromboprophylaxis is lacking and increased awareness regarding risks per se is needed. Large prospective trials will clarify, which patients with CS are at the highest risk and the optimal prevention protocol to minimize risks and maximize efficacy.
Original language | English (US) |
---|---|
Pages (from-to) | 330-336 |
Number of pages | 7 |
Journal | Current Opinion in Endocrinology, Diabetes and Obesity |
Volume | 28 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1 2021 |
Keywords
- Cushing's disease
- Cushing's syndrome
- anticoagulation
- hypercoagulability
- prophylaxis
- thromboembolism
ASJC Scopus subject areas
- Endocrinology
- Nutrition and Dietetics
- Internal Medicine
- Endocrinology, Diabetes and Metabolism